Historically, the first source of tumor-specific T cells have been the patient’s own tumor-infiltrating lymphocytes (TIL), which can be isolated from tumor tissue, expanded using cytokines together with feeder cells or antibody-coated beads, and reinfused after lymphodepleting conditioning with subsequent IL-2 support [8]. The gene discussed is IL2; the disease is neoplasm.